1.993  0.053 (2.73%)		10-24 14:48
Open: 1.95 High: 2.0099 Volume: 11,843		Pre. Close: 1.94 Low: 1.95 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	2.5	1-year :	2.68
Resists	First :	2.14	Second :	2.29
Pivot price	2.02
Supports	First :	1.89	Second :	1.57
MAs	MA(5) :	1.97	MA(20) :	2.02
	MA(100) :	2.41	MA(250) :	4.67
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	20.8	D(3) :	18
RSI	RSI(14): 44.5
52-week	High :	20	Low :	1.89

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ALUR ] has closed above bottom band by 34.3%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.98 - 1.99	1.99 - 2
Low:	1.87 - 1.89	1.89 - 1.9
Close:	1.92 - 1.94	1.94 - 1.96

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Fri, 03 Oct 2025
Allurion Technologies director Milena Alberti-Perez resigns from board - Investing.com

Tue, 19 Aug 2025
ALLURION TECHNOLOGIES, INC. SEC 10-Q Report - TradingView

Tue, 19 Aug 2025
Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq

Wed, 13 Aug 2025
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update - The Globe and Mail

Wed, 13 Aug 2025
Earnings call transcript: Allurion Technologies Q2 2025 sees strategy shift - Investing.com

Tue, 05 Aug 2025
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	8 (M)
Shares Float	4 (M)
Held by Insiders	10.2 (%)
Held by Institutions	40.9 (%)
Shares Short	97 (K)
Shares Short P.Month	106 (K)

EPS	-10.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-8.27
Profit Margin	-154 %
Operating Margin	-205.8 %
Return on Assets (ttm)	-64.8 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-71.4 %
Gross Profit (p.s.)	1.58
Sales Per Share	2.56
EBITDA (p.s.)	-4.86
Qtrly Earnings Growth	0 %
Operating Cash Flow	-42 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-0.2
PEG Ratio	0
Price to Book value	-0.25
Price to Sales	0.77
Price to Cash Flow	-0.37

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.